Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

This was the stock's third consecutive day of gains.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

Vertex Pharmaceuticals' suzetrigine is an investigational ... that's going to set the tone for the commercial side of these products for both Lilly and Novo," BMO Capital Markets managing director ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated ... and $187m from “other products” — essentially older CF therapies — achieving non-GAAP operating ...